ORIC Pharmaceuticals, Inc.
NASDAQORIC enters its August 4 print with short sellers holding a meaningful position — nearly 23% of the free float is currently sold short, up roughly 8% over the past month. Yet the borrow market tells a more relaxed story: availability is running at 305%, meaning three shares are available to borrow for every one already lent out. Cost to borrow has fallen 24% over the past week to…
ORIC put/call ratio surges to 0.1874, a 4.2 standard deviations above the 20-day mean of 0.0922—the most bearish options sentiment in months. Stock down 21.6% in one month on Tazverik withdrawal concerns, despite analyst consensus of "Buy" with $20.36 target.
Snapshot as of 6 Aug 2026
ORIC enters its August 4 print with short sellers holding a meaningful position — nearly 23% of the free float is currently sold short, up roughly 8% over the past month. Yet the borrow market tells a more relaxed…
ORIC Pharmaceuticals reports on June 18 carrying one of the heaviest short positions in its peer group — and a stock that has just broken higher despite it. Short interest is the defining feature of this setup. Bears…
ORIC Pharmaceuticals enters today's earnings report with nearly 30% of its free float sold short — a meaningful bearish overhang for a clinical-stage biotech that has rallied 8% over the past month. Short sellers are…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ORIC — free to start on ORTEX.
Sign up for free →Open ORIC on ORTEX